Document Title
ACP Comments to the Office of National Drug Control Policy regarding the 2026 National Drug Control Strategy
Subject
ACP comments on the President's 2026 National Drug Control Strategy.
Synopsis
ACP comments on the President's 2026 National Drug Control Strategy.
Author
Ryan Crowley
Keywords
Substance use disorders; Behavioral health; Mental health; Behavioral health integration; Primary care; Collaborative care model; Medications for opioid use disorders; buprenorphine; naloxone; morphine; Mental health parity; Harm reduction; Public health; SAMHSA
Creation Date
Modified Date
Pages
4
Document
acp_comments_to_the_office_of_national_drug_control_policy_regarding_the_2026_national_drug_control_strategy_2025.pdf
Adobe Metadata
{"Author":"Ryan Crowley","CreationDate":"2025-06-18T11:06:27-04:00","Creator":"Microsoft\u00ae Word for Microsoft 365","Keywords":"Substance use disorders; Behavioral health; Mental health; Behavioral health integration; Primary care; Collaborative care model; Medications for opioid use disorders; buprenorphine; naloxone; morphine; Mental health parity; Harm reduction; Public health; SAMHSA","ModDate":"2025-06-18T11:17:58-04:00","Producer":"Acrobat Distiller 25.0 (Windows)","Subject":"ACP comments on the President's 2026 National Drug Control Strategy.","Title":"ACP Comments to the Office of National Drug Control Policy regarding the 2026 National Drug Control Strategy","Pages":4,"pdf:producer":"Acrobat Distiller 25.0 (Windows)","pdf:keywords":"Substance use disorders; Behavioral health; Mental health; Behavioral health integration; Primary care; Collaborative care model; Medications for opioid use disorders; buprenorphine; naloxone; morphine; Mental health parity; Harm reduction; Public health; SAMHSA","dc:format":"application\/pdf","dc:creator":"Ryan Crowley","dc:title":"ACP Comments to the Office of National Drug Control Policy regarding the 2026 National Drug Control Strategy","dc:subject":["Substance use disorders","Behavioral health","Mental health","Behavioral health integration","Primary care","Collaborative care model","Medications for opioid use disorders","buprenorphine","naloxone","morphine","Mental health parity","Harm reduction","Public health","SAMHSA"],"dc:description":"ACP comments on the President's 2026 National Drug Control Strategy.","xmp:creatortool":"Microsoft\u00ae Word for Microsoft 365","xmp:createdate":"2025-06-18T11:06:27-04:00","xmp:modifydate":"2025-06-18T11:17:58-04:00","xmp:metadatadate":"2025-06-18T11:17:58-04:00","xmpmm:documentid":"uuid:D1A3D182-1810-44EA-8E5B-70699909E4ED","xmpmm:instanceid":"uuid:295fefa8-2bd0-4a47-a624-d06784476cb0"}
Document Type
Letter
Year
2025